PLK1 and neutropenia: Third, hematologic toxicities such as neutropenia and thrombocytopenia remain the most common dose-limiting adverse events of PLK1 inhibitors and may restrict their use in combination with other myelosuppressive agents, including platinum and paclitaxel.